Summary of Quidel Ortho Conference Call Company Overview - Quidel Ortho was formed by the merger of Quidel and Ortho Clinical Diagnostics in May 2022, focusing on four major business areas: labs, transfusion medicine, point of care, and molecular diagnostics [5][6] - The company reported approximately $2.8 billion in revenue for the full year 2024, with North America contributing 58% of total revenues [6][7] Market Position and Growth Opportunities - The in vitro diagnostics market is valued at $50 billion, growing in the mid-single digits, with Quidel Ortho targeting segments worth approximately $20 billion [9] - The labs business generated $1.4 billion in revenue in 2024, representing about 50% of total revenue, and is expected to grow consistently [10] - The transfusion medicine business, excluding donor screening, generated $523 million in revenue in 2024, with low single-digit growth expected [12] - Point of care contributed $694 million in revenue in 2024, with mid-single-digit growth anticipated [13] - Molecular diagnostics revenue was $24 million in 2024, identified as a significant near-term growth opportunity [13] Strategic Initiatives - The company announced plans to acquire full ownership of Lex Diagnostics for approximately $100 million, aiming to enhance its product portfolio [14][15] - Discontinuation of the Savanna platform was decided due to unsatisfactory clinical trial results, allowing a focus on more promising technologies [15] - The Lex platform is expected to provide rapid and accurate testing, integrating well into existing workflows [16][17] Financial Performance and Cost Management - In Q1, Quidel Ortho achieved a 6% revenue growth, excluding COVID and donor screening, with a 450 basis point improvement in adjusted EBITDA [23] - Cost savings of over $100 million were identified in 2024, with an additional $30 million to $50 million expected in 2025 [22] - The company aims to reduce its net leverage ratio to 2.5 to 3.5 times while expanding margins [24][25] Future Outlook - The company reaffirmed its 2025 financial guidance, targeting mid to high 20s adjusted EBITDA margin [25] - Capital allocation will prioritize business needs, including menu expansion and molecular strategy, while focusing on cash generation and debt reduction [26] - Quidel Ortho is positioned for profitable growth with a strong value proposition and stable underlying business [27]

Investor Conference Call Forward-looking Statements June 3, 2025 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's intent to acquire LEX Diagnostics, molecular diagnostic and other strategic goals, financial guidance and related assumptions and other future financial condition and operating results, ...

QuidelOrtho (QDEL) Update / Briefing June 03, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Quidel Ortho Conference Call. At this time, all participant lines are in listen mode only. For those of you participating in the conference call, there will be an opportunity for you to ask questions at the end of today's prepared remarks. Please note this conference call is being recorded. An audio replay of the conference call will be available on the company's website shortly. A ...

―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET―SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a r ...

Company Overview - QuidelOrtho Corporation, based in San Diego, CA, specializes in in-vitro diagnostics technologies for point-of-care settings, clinical labs, and transfusion medicine, selling products directly to end users and distributors [11] Investment Ratings - QuidelOrtho is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [12] - The company has a Momentum Style Score of B, with shares increasing by 7.1% over the past four weeks [12] Earnings Estimates - Two analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.01 to $2.35 per share [12] - QuidelOrtho has an average earnings surprise of 70.8%, suggesting strong performance relative to expectations [12] Investment Considerations - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, QuidelOrtho is recommended for investors' consideration [13]

Company Overview - QuidelOrtho Corporation, based in San Diego, CA, specializes in in-vitro diagnostics technologies for point-of-care settings, clinical labs, and transfusion medicine [11] - The company sells products directly to end users and distributors for professional use in various healthcare settings, including hospitals, clinical laboratories, and pharmacies [11] Investment Potential - QuidelOrtho is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating strong potential for growth [12] - The company has a Growth Style Score of A, forecasting a year-over-year earnings growth of 27% for the current fiscal year [12] - Recent upward revisions in earnings estimates by analysts have led to an increase in the Zacks Consensus Estimate to $2.35 per share, reflecting a positive outlook [12] - QuidelOrtho has demonstrated an average earnings surprise of 70.8%, suggesting strong performance relative to expectations [12] Summary of Style Scores - The VGM Score combines value, growth, and momentum characteristics, making it a comprehensive indicator for assessing stocks [6] - The Growth Style Score focuses on a company's financial strength and future outlook, which is particularly relevant for QuidelOrtho given its projected earnings growth [4] - The combination of a solid Zacks Rank and high Style Scores positions QuidelOrtho as a noteworthy option for investors [13]

Company Overview - QuidelOrtho Corporation, based in San Diego, CA, specializes in in-vitro diagnostics technologies for point-of-care settings, clinical labs, and transfusion medicine, selling products directly to end users and distributors [11] Investment Ratings - QuidelOrtho is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid position in the market [12] - The company has a Growth Style Score of A, forecasting a year-over-year earnings growth of 27% for the current fiscal year [12] Earnings Estimates - Two analysts have revised their earnings estimates upwards in the last 60 days for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.01 to $2.35 per share [12] - QuidelOrtho boasts an average earnings surprise of 70.8%, suggesting strong performance relative to expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, QuidelOrtho is recommended for investors looking for growth opportunities [13]

Core Viewpoint - QuidelOrtho Corporation reported strong adjusted earnings per share (EPS) of 74 cents for Q1 2025, reflecting a 68.2% year-over-year increase and surpassing the Zacks Consensus Estimate by 27.6% [1] Financial Performance - Revenues for Q1 2025 were $692.8 million, a decrease of 2.6% year-over-year, but slightly above the Zacks Consensus Estimate by 0.3% [2] - Respiratory revenues were $119.8 million, down 12.8% year-over-year, while Non-Respiratory revenues were $573 million, down 0.1% but up 1.7% at constant exchange rates [2] - Adjusted gross profit improved 2.7% year-over-year to $346.9 million, with an adjusted gross margin of 50.1%, an increase of 260 basis points [9] - Adjusted operating profit totaled $107.6 million, a 36% improvement from the prior year, with an adjusted operating margin of 15.5%, up 440 basis points [10] Business Unit Performance - Labs revenues were $373.1 million, up 4.5% year-over-year [4] - Immunohematology revenues were $128.5 million, up 1.2% year-over-year [5] - Donor Screening revenues were $12.8 million, down 61.6% year-over-year [5] - Point of Care revenues were $170.8 million, down 8.5% year-over-year [5] - Molecular Diagnostics revenues totaled $7.6 million, up 5.6% year-over-year [6] Geographical Performance - North America revenues were $406.7 million, down 6.3% year-over-year [7] - EMEA revenues were $88.9 million, up 4.8% year-over-year [7] - Revenues from China were $75 million, down 1.4% year-over-year [8] - Other regions generated $122.2 million, up 5.2% year-over-year [8] Financial Position - Cash and cash equivalents at the end of Q1 2025 were $127.1 million, up from $98.3 million at the end of 2024 [11] - Total debt at the end of Q1 2025 was $2.49 billion, slightly up from $2.48 billion at the end of 2024 [11] - Net cash provided by operating activities was $65.6 million, compared to a net cash used of $0.7 million a year ago [11] Guidance and Outlook - QuidelOrtho expects total revenues for 2025 to be in the range of $2.60 billion to $2.81 billion, with a consensus estimate of $2.70 billion [12] - The company anticipates stable growth across most business lines, particularly in Labs and Immunohematology, with expected COVID-19 revenues of $110-$140 million for 2025 [13][14] - Management expressed confidence in mitigating a projected gross tariff impact of $30–$40 million in 2025 through various strategies [17]

Company Performance - QuidelOrtho reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and up from $0.44 per share a year ago, representing an earnings surprise of 27.59% [1] - The company posted revenues of $692.8 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.30%, although this is a decrease from year-ago revenues of $711 million [2] - Over the last four quarters, QuidelOrtho has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - QuidelOrtho shares have declined approximately 41.8% since the beginning of the year, in contrast to the S&P 500's decline of 4.7% [3] - The current Zacks Rank for QuidelOrtho is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.14 on revenues of $621.72 million, and for the current fiscal year, it is $2.31 on revenues of $2.7 billion [7] - The outlook for the Medical - Products industry, to which QuidelOrtho belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact the stock's performance [8]

May 7, 2025 QuidelOrtho First Quarter 2025 Financial Results QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 2 $160M 2 Total Revenue $693M North America 57% Other 19% China 12% EMEA 12% Recurring 82% Business Unit Geography Category Labs 51% Point of Care 26% 4 Adjusted EBITDA 23% Margin2 3 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking stat ...